RxDoctor Payments Data

Kristin Farmer, NP

Primary Care · Amarillo, TXNPI 1356092423

Payments from drug & device makers

$1,563in general payments, 2019–2025

Across 86 payments — averaging $18.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$833
  • Pfizer$254
  • Teva Pharmaceuticals USA, Inc.$202
  • Biohaven Pharmaceutical Holding Company Ltd.$64
  • Organon$43
  • Upsher-smith Laboratories LLC$32
  • plus $134 from 6 others

What the payments were for

  • Food & beverage$1,563100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,563 in reported general payments places this provider in the 80th percentile of 563 primary care providers in Texas.

See all primary care providers in Texas

Medicare billing

Part B allowed, 2024
$15,037
Medicare patients
47
Services billed
181

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide55$56,495
Trelegy ElliptaFluticasone/Umeclidin/Vilanter50$33,629
WegovySemaglutide18$26,422
Nurtec OdtRimegepant Sulfate12$23,589
JardianceEmpagliflozin16$22,986
OzempicSemaglutide21$21,776
SymbicortBudesonide/Formoterol Fumarate23$4,939
Lidocaine33$2,993
PremarinEstrogens, Conjugated13$2,750
Gabapentin88$1,977
Duloxetine Hcl56$1,614
Risedronate Sodium13$931
Esomeprazole Magnesium17$906
Albuterol Sulfate HfaAlbuterol Sulfate34$847
Levothyroxine Sodium103$798

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$31$56,49555 claims
PfizerNurtec Odt, Premarin$254$26,33925 claims
AstraZenecaSymbicort$22$4,93923 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 563 primary care providers in Texas.

Other primary care in Amarillo

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →